Aribio Restructures Group Around Holdings... "AR1001 to Achieve 1 Trillion Won in Revenue by 2030"

Establishing an Integrated Framework for Prevention, Treatment, and Management of Degenerative Brain Diseases
Global Phase III Results to Be Announced in November; Targeting U.S. Approval in 2028
Aribio–Holdings Merger Withdrawn: "All Options Un

Aribio Group is establishing an end-to-end business system that covers prevention, treatment, and management of degenerative brain diseases by concentrating the capabilities of its affiliates under the leadership of Aribio Holdings. The group plans to accelerate its new drug commercialization efforts beginning with the announcement of global Phase 3 clinical trial results for the Alzheimer’s drug candidate ‘AR1001’ while expanding its business scope to include vaccines and brain health management.

On October 1, Aribio Holdings, Aribio, and Aribio Lab held the ‘2026 Aribio Group Vision Declaration Ceremony’ at Seoul Dragon City in Yongsan-gu, Seoul, where they unveiled this business strategy and growth roadmap. Under the slogan ‘One Name, One Vision,’ the three companies agreed to create a system where Aribio Lab is responsible for prevention, Aribio for treatment, and Aribio Holdings for management, as well as supporting the group’s capital and infrastructure.

Jaejun Chung, Chairman of Aribio Group, is speaking at the "2026 Aribio Group Vision Declaration Ceremony" held on the 1st at Seoul Dragon City in Yongsan-gu, Seoul. Photo by Seongmin Lee

Jaejun Chung, Chairman of Aribio Group, stated, “Dementia progresses over about 20 years, from the asymptomatic stage to mild cognitive impairment (MCI) and then to mild, moderate, and severe dementia, so a comprehensive solution encompassing the entire cycle is necessary. Our goal is to integrate prevention, treatment, and management into a single platform, taking responsibility for the full spectrum of brain diseases.”

The next major milestone is the announcement of the global Phase 3 clinical trial results for AR1001. The Phase 3 trial of AR1001 enrolled 1,535 patients across 230 clinical sites in 13 countries, and among them, 1,348 completed the 52-week main clinical study. Aribio plans to present the topline results at the CTAD 2026 Alzheimer’s Clinical Trials Conference in Boston, U.S., in November, after data organization is completed.

After announcing the clinical trial results this year, the company will begin preparations for a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA), aiming to submit the application in 2027 and obtain approval in 2028. The company is also targeting sales of 1 trillion won in 2030 by expanding AR1001’s indications and accelerating the development of follow-up pipelines after 2029.

Fred Kim, Head of Aribio’s U.S. branch, said, “We have already begun modular preparations for the application for approval and have formed a task force. We plan to leverage regulatory systems such as priority review to move up the commercialization timeline as much as possible.” He added, “Existing monoclonal antibody therapies are generally priced at 40 to 60 million won per year, but we plan to offer our product at a lower price. However, specific pricing will be determined through discussions with partners in each country.”

Eunyeong Jeon, Vice President of Arribaio Lab, is speaking at the '2026 Arribaio Group Vision Declaration Ceremony' held on the 1st at Seoul Dragon City in Yongsan-gu, Seoul. Photo by Seongmin Lee

Aribio Lab is developing an Alzheimer’s vaccine using its proprietary immune adjuvant platforms ‘L-pampo’ and ‘Lipo-pam.’ The company is currently conducting Phase 2 clinical trials of a shingles vaccine and is developing preventative and therapeutic vaccines for hepatitis B, among others. Their strategy is to leverage the immuno-boosting technology and clinical experience gained during shingles vaccine development to expand into Alzheimer’s vaccines.

Eunyeong Jeon, Vice President of Aribio Lab, stated, “We plan to secure topline results for the Phase 2 shingles vaccine trial between 2026 and 2027 and begin preclinical studies for the Alzheimer’s vaccine. By 2028–2029, we will secure proof of concept (PoC) for the preclinical Alzheimer’s vaccine, preparing for clinical entry, and after 2030, we will proceed with clinical development and commercialization.”

Aribio Holdings is responsible for providing the funding and infrastructure necessary for these businesses. While strengthening cash flow from its existing lighting and electrical construction operations, the company is expanding into high value-added areas such as semiconductor factory and AI data center electrical construction, human-centric lighting (HCL), and medical specialty lighting. It also plans to gradually establish a group-dedicated AI computing infrastructure that utilizes the research and clinical data from Aribio and Aribio Lab.

Kim Hoe-cheon, CEO of Aribio Holdings, said, “Our basic principle is to provide funding through operating cash flow generated by our core business. Raising funds directly from the capital market will be limited to when strictly necessary.” The holding company intends to reinvest funds secured from its own business into expanding subsidiaries’ equity, R&D, and new business initiatives, creating a structure in which group achievements translate directly into increased corporate and shareholder value for Aribio Holdings.

The company is also revisiting Aribio’s entry into the capital markets following the recent withdrawal of the merger between Aribio and Aribio Holdings. Chairman Chung stated regarding future listing plans, “We are reconsidering all options from the baseline. We are exploring every possible path centered around the holding company to ensure the best outcome for shareholders and the group.”

He added, “The topline data from the global Phase 3 trial to be released at CTAD in November will be a critical milestone for the group’s direction. By uniting the three pillars of treatment, prevention, and management under a single vision, we aim to take on the challenge not only of degenerative brain diseases but also of the broader issues of aging.”

This content was produced with the assistance of AI translation services.